Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) have earned a consensus rating of “Buy” from the five brokerages that are presently covering the firm. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $15.25.

A number of research firms recently issued reports on NBRV. Zacks Investment Research lowered shares of Nabriva Therapeutics AG from a “buy” rating to a “hold” rating and set a $8.25 target price on the stock. in a research note on Friday, September 23rd. Wedbush reiterated an “outperform” rating and issued a $17.00 target price on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th. HC Wainwright began coverage on shares of Nabriva Therapeutics AG in a research note on Thursday, September 8th. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Leerink Swann reiterated an “outperform” rating and issued a $14.00 target price on shares of Nabriva Therapeutics AG in a research note on Thursday, October 27th.

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 4.98 on Thursday. The stock’s market capitalization is $105.81 million. The stock’s 50 day moving average is $6.17 and its 200 day moving average is $7.37. Nabriva Therapeutics AG has a 52 week low of $4.02 and a 52 week high of $10.69.

Hedge funds have recently bought and sold shares of the company. Baker BROS. Advisors LP bought a new stake in Nabriva Therapeutics AG during the third quarter valued at about $2,468,000. Jackson Park Capital LLC bought a new stake in Nabriva Therapeutics AG during the second quarter valued at about $195,000. Opaleye Management Inc. raised its stake in Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock valued at $2,453,000 after buying an additional 53,800 shares in the last quarter. Finally, Vivo Capital LLC bought a new stake in Nabriva Therapeutics AG during the first quarter valued at about $28,239,000. Institutional investors own 63.05% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).

5 Day Chart for NASDAQ:NBRV

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.